Global Insomnia Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• May 2022: Idorsia Ltd received marketing authorization from the European Commission for QUVIVIQ, which is is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning.

• January 2022: Idorsia received approval from the United States Food and Drug Administration for QUVIVIQ 25 and 50 mg for the treatment of adults with insomnia, characterized by difficulties with sleep onset and /or sleep maintenance.

The Global Insomnia Market is segmented by Drug Formulation, Treatment Type, and Disease Condition, reflecting a comprehensive approach to addressing this widespread sleep disorder.

By Drug Formulation, the market encompasses various forms such as tablets, capsules, liquids, and extended-release formulations, designed to meet diverse patient preferences and medical requirements. Tablets and capsules dominate the segment due to ease of administration, stability, and widespread availability. Liquid formulations cater to individuals with swallowing difficulties, while extended-release formulations offer prolonged effects to aid in maintaining sleep throughout the night.

Segmentation by Treatment Type highlights a broad spectrum of therapeutic options, including pharmacological and non-pharmacological approaches. Pharmacological treatments include benzodiazepines, nonbenzodiazepines, orexin antagonists, melatonin receptor agonists, and antidepressants, which target specific mechanisms to induce and maintain sleep. Non-pharmacological treatments, such as cognitive-behavioral therapy for insomnia (CBT-I) and the use of devices like wearable monitors and neurostimulation, cater to patients seeking alternative or complementary solutions to medication.

By Disease Condition, the market addresses acute insomnia, chronic insomnia, and comorbid insomnia. Acute insomnia, often triggered by stress or situational factors, requires short-term interventions such as sedatives or behavioral therapy. Chronic insomnia, a persistent condition lasting months or years, demands a combination of pharmacological and cognitive-behavioral therapies to improve sleep hygiene and address underlying causes. Comorbid insomnia, which coexists with other health issues like anxiety, depression, or chronic pain, requires tailored treatments targeting both insomnia and the associated conditions.

This segmentation underscores the market's diversity in catering to the varied needs of insomnia patients. It also highlights ongoing innovation in drug delivery and treatment methods to enhance efficacy, safety, and patient compliance.

Global Insomnia Segment Analysis

In this report, the Global Insomnia Market has been segmented by Drug Formulation, Treatment Type, Diseases Condition, and Geography.

Global Insomnia Market, Segmentation by Drug Formulation

The Global Insomnia Market has been segmented by Drug Formulation into Capsules, Tablet, and Others.

Capsules are a popular drug formulation in the insomnia market due to their ease of swallowing and the ability to encapsulate both liquid and solid medications. Capsules can be designed to deliver medication in a controlled-release manner, which can be particularly beneficial for insomnia treatments that need to maintain therapeutic levels of the drug throughout the night. The encapsulation also helps in masking the taste of the drug, making it more palatable for patients. Additionally, capsules can be rapidly absorbed, leading to quicker onset of action, which is a critical factor for patients seeking immediate relief from insomnia.

Tablets are another widely used formulation in the insomnia market. They are preferred for their stability, longer shelf life, and the ability to incorporate a wide range of dosages and combinations of active ingredients. Tablets can be designed in various forms, such as immediate-release, extended-release, or sublingual, to cater to different therapeutic needs. Immediate-release tablets provide quick relief, while extended-release tablets offer prolonged therapeutic effects, helping patients stay asleep throughout the night. The sublingual tablets, which dissolve under the tongue, offer rapid absorption into the bloodstream, making them ideal for patients who require fast-acting solutions.

Global Insomnia Market, Segmentation by Treatment Type

The Global Insomnia Market has been segmented by Treatment Type into Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonist, Melatonin Antagonist, Devices, and Others.

Benzodiazepines are one of the oldest treatment options for insomnia, known for their sedative effects and ability to reduce the time taken to fall asleep. However, concerns over dependency and side effects have led to a shift toward newer alternatives.

Nonbenzodiazepines, also referred to as "Z-drugs," have become a popular choice due to their improved safety profiles and reduced risk of dependency compared to traditional benzodiazepines. These drugs target specific receptors in the brain to promote sleep and are often prescribed for short-term use.

Antidepressants are commonly used for insomnia when it is associated with co-occurring conditions such as anxiety or depression. Certain antidepressants have sedative properties that help improve sleep quality, offering dual benefits for patients with overlapping symptoms.

Orexin Antagonists represent an innovative approach by targeting the orexin system, which regulates wakefulness. These drugs aim to reduce overactive wake signals in the brain, promoting natural sleep patterns without excessive sedation.

Melatonin Antagonists work by modulating the body's circadian rhythm. These treatments are particularly effective for patients with delayed sleep phase disorder or insomnia caused by disruptions to their natural sleep-wake cycle.

Devices such as wearable sleep monitors and neurostimulation devices provide non-pharmacological options for managing insomnia. They are increasingly being adopted by patients who prefer to avoid medication or seek complementary solutions to improve sleep.

The Others category encompasses herbal remedies, behavioral therapies, and alternative treatments like acupuncture, which are gaining attention as part of a holistic approach to insomnia management.

This segmentation showcases the multifaceted strategies available in the insomnia market, addressing various patient needs and conditions contributing to sleep disorders.

Global Insomnia Market, Segmentation by DIseases Condition

The Global Insomnia Market has been segmented by DIseases Condition into Poor Quality Of Sleep, Sleep Maintenance, and Others.

Poor quality of sleep encompasses conditions where individuals have difficulty achieving restful and restorative sleep, even if they can fall asleep easily. This category often includes patients who experience frequent awakenings, light sleep, and non-restorative sleep patterns. Treatments for poor quality of sleep focus on improving the overall sleep architecture and enhancing the depth and quality of sleep. Pharmacological options, such as sedative-hypnotics and melatonin receptor agonists, are commonly used to enhance sleep quality. Additionally, non-pharmacological approaches, including cognitive behavioral therapy for insomnia (CBT-I), relaxation techniques, and sleep hygiene education, play a crucial role in addressing the underlying factors contributing to poor sleep quality.

Sleep maintenance insomnia refers to difficulty staying asleep through the night, leading to frequent awakenings and an inability to return to sleep. This condition can significantly disrupt the sleep cycle and result in insufficient sleep duration, leaving individuals feeling fatigued and unrested. Treatment strategies for sleep maintenance insomnia often involve medications that have a longer duration of action to help patients stay asleep throughout the night. Extended-release formulations of hypnotics and other sleep aids are commonly prescribed to manage sleep maintenance issues. Additionally, behavioral interventions and lifestyle modifications aimed at reducing nocturnal awakenings and promoting continuous sleep are essential components of a comprehensive treatment plan.

Global Insomnia Market, Segmentation by Geography

In this report, the Global Insomnia Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Insomnia Market Share (%), by Geographical Region, 2024

North America, particularly the United States and Canada, is expected to dominate the insomnia market during the forecast period. The high prevalence of insomnia, advanced healthcare infrastructure, and robust pharmaceutical industry drive market growth in this region. Additionally, increased awareness about the impact of sleep disorders on overall health, combined with a strong focus on mental health, supports the demand for both pharmacological and non-pharmacological treatments. The presence of major market players and continuous advancements in sleep medicine also contribute to North America's leading position in the insomnia market.

Europe represents a significant market for insomnia treatments, with countries like Germany, the United Kingdom, France, and Italy at the forefront. The region benefits from a large population affected by sleep disorders, well-established healthcare systems, and supportive government initiatives aimed at improving mental health and sleep hygiene. Increasing adoption of advanced therapies, including cognitive behavioral therapy for insomnia (CBT-I) and novel pharmacological treatments, is driving market growth. Additionally, Europe’s aging population, which is more susceptible to insomnia, further fuels the demand for effective treatments and interventions.

The Asia Pacific region is poised for substantial growth in the insomnia market, driven by rising healthcare expenditure, growing awareness about sleep disorders, and expanding access to medical care in countries like China, India, Japan, and Australia. Rapid urbanization, increased stress levels, and changing lifestyles contribute to the rising prevalence of insomnia in this region. As a result, there is a growing demand for both traditional and innovative treatment options, including herbal supplements and modern pharmaceuticals. The increasing focus on mental health and well-being, along with the expansion of healthcare infrastructure, supports the market's growth trajectory in Asia Pacific.

In the Middle East and Africa, the insomnia market is characterized by improving healthcare infrastructure and increasing awareness about the importance of sleep health. Countries like the United Arab Emirates, Saudi Arabia, and South Africa are witnessing a rise in the prevalence of sleep disorders, prompting greater demand for insomnia treatments. Government initiatives to enhance healthcare services and increasing investment in medical facilities contribute to market growth. However, challenges such as limited access to specialized sleep clinics and varying levels of awareness about insomnia may affect the pace of market expansion in this region.

Latin America presents a dynamic and growing market for insomnia treatments, driven by improving healthcare systems, rising prevalence of sleep disorders, and increasing healthcare expenditure in countries like Brazil, Mexico, and Argentina. The region is seeing a gradual shift towards recognizing the importance of mental health and sleep hygiene, supported by public health initiatives and growing access to medical care. The presence of both local and international pharmaceutical companies offering a range of treatment options, from traditional remedies to advanced pharmacological solutions, further propels market growth in Latin America.

This report provides an in depth analysis of various factors that impact the dynamics of Global Insomnia Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Aging Population
• Increased Awareness
• Growth in Mental Health Disorders

• Advancements in Therapeutics - Advancements in therapeutics are significantly driving the growth of the global insomnia market, providing patients with more effective and targeted treatment options. Innovations in pharmacological treatments, including the development of new classes of medications such as dual orexin receptor antagonists (DORAs), offer improved efficacy and safety profiles compared to traditional benzodiazepines and non-benzodiazepine hypnotics. These advancements address common issues such as the risk of dependency and adverse side effects, enhancing patient adherence and satisfaction with their insomnia treatments.

  The advent of personalized medicine is transforming insomnia therapy by allowing for treatments tailored to individual patient profiles. Genetic and biomarker research is paving the way for the development of personalized treatment plans that consider a patient's unique genetic makeup, lifestyle, and specific sleep disorder characteristics. This approach increases the likelihood of treatment success and reduces the risk of adverse reactions, making it a promising direction for future insomnia therapeutics.

  Advancements in non-pharmacological therapies, such as cognitive behavioral therapy for insomnia (CBT-I) delivered through digital platforms, are expanding treatment options for patients. Digital health technologies, including mobile apps and telemedicine, provide convenient access to evidence-based therapies that can be customized and scaled to meet the needs of diverse populations. These innovations not only improve accessibility and affordability of insomnia treatments but also promote long-term management of sleep disorders, contributing to the overall growth and development of the global insomnia market.

Restraints

• High Cost of Treatment
• Risk of Dependency
• Limited Availability of Effective Therapies

• Stringent Regulatory Requirements - Stringent regulatory requirements present a significant challenge in the global insomnia market, impacting the development, approval, and commercialization of new therapies. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) enforce rigorous standards to ensure the safety, efficacy, and quality of insomnia medications and treatments. These stringent requirements often lead to prolonged development timelines and increased costs for pharmaceutical companies, potentially delaying the availability of innovative therapies to patients.

  The extensive clinical trials and comprehensive documentation needed to meet regulatory standards are particularly burdensome for smaller biotech and pharmaceutical firms with limited resources. These companies must invest heavily in research and development, as well as in regulatory affairs expertise, to navigate the complex approval processes. Additionally, the requirement for post-marketing surveillance and ongoing safety monitoring adds to the long-term financial and operational burden, affecting the overall market dynamics and competition.

  Varying regulatory requirements across different regions add another layer of complexity for companies aiming to launch insomnia treatments globally. Harmonizing these regulations to streamline the approval process remains a significant challenge. Despite these obstacles, stringent regulatory requirements are essential for ensuring that new insomnia treatments are safe and effective for patients. However, the industry must continuously adapt and innovate to meet these challenges while advancing the development of new therapies to address the unmet needs of insomnia sufferers worldwide.

Opportunities

• Growing Demand for Natural Remedies
• Expansion in Emerging Markets
• Research and Development Investments

• Personalized Medicine Approaches - Personalized medicine approaches are revolutionizing the treatment landscape of the global insomnia market by tailoring therapies to individual patient needs. This method involves using genetic, environmental, and lifestyle information to design and optimize treatment plans specifically suited to each patient. By identifying genetic markers and other individual characteristics that influence how patients respond to various treatments, healthcare providers can prescribe the most effective medications and therapeutic interventions, thereby enhancing treatment outcomes and minimizing adverse effects.

  Personalized medicine in insomnia treatment is the ability to move away from a one-size-fits-all approach. Traditional insomnia therapies often rely on a trial-and-error process to find the right medication and dosage, which can be time-consuming and frustrating for patients. Personalized medicine, on the other hand, allows for a more precise and targeted approach, reducing the likelihood of ineffective treatments and helping patients achieve better sleep more quickly. This approach can significantly improve patient satisfaction and adherence to treatment regimens.

  Advancements in technology and data analytics are facilitating the implementation of personalized medicine in insomnia care. Tools such as genetic testing, wearable sleep trackers, and artificial intelligence algorithms enable the collection and analysis of detailed patient data. This information can be used to identify specific sleep patterns, potential triggers for insomnia, and the best therapeutic strategies. As personalized medicine continues to evolve, it holds the promise of transforming insomnia treatment by providing more accurate, efficient, and individualized care, ultimately improving the quality of life for millions of people affected by sleep disorders.

Key players in Global Insomnia Market include :

• Pfizer Inc
• Takeda Pharmaceutical Company Ltd
• Sanofi S.A
• Idorsia Pharmaceuticals Ltd
• Electromedical
• Merck & Co
• Aurobindo Pharma Limited
• Astellas Pharma

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis